MediLexicon Logo
MediLexicon Logo
Abbreviations        Abbrev Definitions        Dictionary        ICD Codes        Equipment        Hospitals        Drugs        More..

BeneFIX (coagulation Factor IX (recombinant))

Company: Genetics Institute
Approval Status: Recommended for approval December 1996
Treatment for: hemophilia B
Areas: Hematology
Possible similar drugs: BeneFIX

| General Information | Additional Information |

General Information

BeneFIX, Coagulation Factor IX (Recombinant) has been approved as the first recombinant blood clotting therapy for hemophilia B. BeneFIX eliminates the risk of transmitting blood- borne viruses such as hepatitis which have been associated with Factor IX therapies made from human plasma.

As a result of viral contamination from earlier plasma-derived clotting therapies, over 20% of U.S. hemophilia patients are HIV positive and over 70% have hepatitis. Since BeneFIX is made through recombinant technology, without the addition of blood or plasma products, it eliminates the risk of potential blood-borne viral contamination. Further, the supply of BeneFIX does not depend on blood donors.

Additional Information

An inherited disorder that almost exclusively affects males, hemophilia B is caused by a deficiency or defect in Factor IX, one of a number of proteins involved in blood clotting. Factor IX deficiency results in frequent hemorrhages that can be crippling and, at times, life-threatening. The disorder affects about 7,000 people in North America, Europe and Japan (approximately 3,000 patients in the United States).

< back to top

BeneFIX Drug Information

The Benefix drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

MediLexicon International Ltd Logo

Privacy Policy   |    Disclaimer   |    Contact / Feedback

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2016 All rights reserved.